Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Public ClinicalTrials.gov record NCT06268665. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy. Eligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).
Study identification
- NCT ID
- NCT06268665
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 86 participants
Conditions and interventions
Conditions
- Breast Cancer
- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage III
- Breast Cancer Stage IV
- Invasive Breast Cancer
- Ovarian Cancer
- Ovarian Cancer Stage 1
- Ovarian Cancer Stage II
- Ovarian Cancer Stage III
- Ovarian Cancer Stage IV
- Ovarian Cancer Stage IA
- Ovarian Cancer Stage IB
- Ovarian Cancer Stage IC
- Ovarian Cancer Stage 2
- Ovarian Cancer Stage 3
- Ovarian Cancer Stage IIIb
- Ovarian Cancer Stage IIIC
- Breast Cancer Stage IIIA
- Breast Cancer Invasive
- Breast Cancer, Stage IA
- Breast Cancer, Stage IB
- Breast Cancer Stage IIA
- Breast Cancer Stage IIB
- Breast Cancer Stage IIIB
- Breast Cancer Stage IIIc
- Cancer, Breast
- Tumors, Breast
- Mammary Cancer
- Mammary Carcinoma
- Breast Carcinoma
- Breast Neoplasm
- Malignant Breast Neoplasm
- Malignant Tumor of Breast
- Cancer of Ovary
- Ovary Cancer
- Ovary Neoplasm
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 14, 2024
- Primary completion
- Sep 30, 2027
- Completion
- Nov 30, 2027
- Last update posted
- Mar 3, 2026
2024 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95827 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06268665, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06268665 live on ClinicalTrials.gov.